TY  - JOUR
AU  - Martin-Algarra, Salvador
AU  - Soriano, Virtudes
AU  - Fernandez-Morales, Luis
AU  - Berciano-Guerrero, Miguel-Angel
AU  - Mujika, Karmele
AU  - Manzano, Jose Luis
AU  - Puertolas-Hernandez, Teresa 
AU  - Soria, Ainara
AU  - Rodriguez-Abreu, Delvys
AU  - Espinosa-Arranz, Enrique
AU  - Medina-Martinez, Javier
AU  - Marquez-Rodas, Ivan
AU  - Rubio-Casadevall, Jordi
AU  - Ortega, Maria Eugenia 
AU  - Jurado-Garcia, Jose Miguel
AU  - Lecumberri-Biurrun, Maria Jose
AU  - Palacio, Isabel
AU  - Rodriguez-de-la-Borbolla-Artacho, Maria 
AU  - Perez-Altozano, Javier
AU  - Castellon-Rubio, Victoria Eugenia
AU  - Garcia, Almudena
AU  - Luna, Pablo
AU  - Ballesteros, Anabel
AU  - Fernandez, Ovidio
AU  - Lopez-Martin, Jose Antonio
AU  - Berrocal, Alfonso
AU  - Arance, Ana
PY  - 2017
DO  - 10.1097/MD.0000000000009523
SN  - 0025-7974
UR  - http://hdl.handle.net/10668/18962
T2  - Medicine
AB  - The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with...
LA  - en
PB  - Wolters Kluwer Health
KW  - BRAF
KW  - BRAF inhibitors
KW  - compassionate use
KW  - dabrafenib
KW  - metastatic melanoma
KW  - trametinib
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Braf inhibition
KW  - Combination
KW  - Multicenter
KW  - Mutations
KW  - Survival
KW  - Therapy
KW  - Vemurafenib
KW  - Resistance
TI  - Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
TY  - research article
VL  - 96
ER  -